Sanjay Chanda is SVP & Drug Development at Anacor Pharmaceuticals, Inc. (ANAC). They have made 2 open-market trades across 1 company since 2014, most recently 2026-02-20.
CIK 0001571820
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANTX | 118,823 | $402K |
| ANAC | 29,135 | $297K |
| Total | $699K |
Shares reported on the most recent Form 4, priced at the 2026-02-23 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANTX | SELL | 2026-01-05 | 2026-01-07 | $1.01 | $9K | +7.3% | -0.9% | +200.0% |
| ANTX | SELL | 2025-01-03 | 2025-01-07 | $1.34 | $4K | -5.2% | -17.9% | -7.5% |
| ANAC | SELL · 10b5-1 | 2015-03-04 | 2015-03-04 | $45.00 | $225K | -19.4% | +2.3% | +2.3% |
| ANAC | SELL · 10b5-1 | 2014-11-26 | 2014-12-01 | $35.00 | $175K | -19.4% | +2.3% | +2.3% |
| ANAC | SELL · 10b5-1 | 2014-09-10 | 2014-09-12 | $24.25 | $243K | -19.4% | +2.3% | +2.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.